Table 2.

Primary and secondary outcomes for patients in the hospital

Variable	Exenatide (N = 47)	Exe + basal (N = 51)	Basal bolus (N = 52)	P
Overall BG, mg/dL*	177.1 ± 41	154.1 ± 39	166.1 ± 40	0.03
Glucose readings within range, mg/dL
% BG readings <70*	0.0 ± 0.0	0.4 ± 1.5	1.1 ± 4.1	0.06
% BG readings 70–139*†	23.9 ± 31	39.6 ± 33	36.4 ± 32	0.05
% BG readings 70–180*†	62.3 ± 39	77.7 ± 31	63.3 ± 31	0.02
% BG readings 180–240*†	27.4 ± 31.9	16.8 ± 24.8	24.4 ± 27.5	0.19
% BG readings >240*	10.4 ± 24	5.1 ± 16	11.2 ± 23	0.08
Subjects with hypoglycemia, n (%)*
BG <70 mg/dL	0 (0)	3 (6)	6 (12)	0.06
BG <54 mg/dL	0 (0)	1 (2)	2 (4)	0.77
BG <40 mg/dL	0 (0)	0 (0)	0 (0)	NA
Glucose checks, number/day*	2.7 ± 1.0	2.9 ± 0.9	2.7 ± 1.0	0.46
Insulin administration*
Total insulin, units/day	8.1 ± 5	17.7 ± 11	28.0 ± 15	<0.001
Total basal insulin, units/day	—	18.5 ± 7	22.0 ± 8	0.12
Total corrective insulin, units/day	8.1 ± 5	5.2 ± 3	6.3 ± 3	0.01
Total number of injections/day‡	2.8 ± 1	3.1 ± 1	2.6 ± 1	0.04
LOS, days, median (IQR)	4.0 (2.0, 8.0)	5.0 (3.0, 7.0)	4.0 (2.0, 5.0)	0.23
Adverse events, n (%)
Nausea	5 (11)	5 (10)	1 (2)	0.17
Vomiting	1 (2)	3 (6)	0 (0)	0.17
Nausea or vomiting	5 (11)	5 (10)	1 (2)	0.17
Medication discontinued owing to AE, n (%)	3 (6)	0 (0)	0 (0)	0.03
Treatment failure‖	2 (4)	0 (0)	0 (0)	0.10
Hospital complications, n (%)
Composite complications	3 (6)	6 (12)	4 (8)	0.63
Myocardial infarction	0 (0)	0 (0)	0 (0)	NA
Congestive heart failure	0 (0)	0 (0)	1 (2)	>0.99
Acute renal failure	3 (6)	6 (12)	3 (6)	0.52
Respiratory failure	1 (2)	0 (0)	0 (0)	0.31

Data are means ± SD unless otherwise indicated. AE, adverse event; Exe, exenatide; IQR, interquartile range.

*Values included from day 2 to day 10.

†Glycemic targets included in post hoc analysis.

‡Total number of injections includes insulin and exenatide injections.

‖Treatment failure defined by 3 consecutive days with fasting BG >240 mg/dL or average daily BG >240 mg/dL.